2016 Leads Prescription 
pharmaphorum
JANUARY 12, 2023
As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Drug diversion is the channelling of prescription drugs from a medical source into the illegal market. The post The rise of prescription drug abuse and drug diversion appeared first on.
World of DTC Marketing
JUNE 18, 2021
This report is going to lead to more calls to limit DTC advertising. 1ne: Medicare Parts B and D and beneficiaries spent $560 billion on drugs from 2016 through 2018, $324 billion spent on advertised drugs. Do DTC ads lead to increased patient knowledge of chronic health issues? So let’s look at the contents.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
SEPTEMBER 9, 2021
SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.
World of DTC Marketing
SEPTEMBER 7, 2022
In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. According to JAMA , “in a cross-sectional study, between May 1, 2016, and May 31, 2021, there were 207 cancer drug approvals in oncology and malignant hematology. ” The U.S.
Legacy MEDSearch
MARCH 15, 2023
Founded in 2016, LIVMOR developed the Halo+ Atrial Fibrillation (AF) Detection System, the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.
European Pharmaceutical Review
JULY 4, 2024
1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. 2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 3 Is two too few? 2012/1916).
Pharmaceutical Technology
SEPTEMBER 23, 2022
Current treatment options for DES are dominated by a mix of prescription and over-the-counter (OTC) products. Competing against Restasis are Novartis’ Xiidra (lifitegrast ophthalmic solution 5%), which launched in the US in 2016, and Sun Pharma’s Cequa (cyclosporine ophthalmic solution 0.09%), which launched in the US in 2019.
Expert insights. Personalized for you.
90 
Let's personalize your content